The FDA has granted accelerated approval to Avmapki (avutometinib) plus Fakzynja (defactinib) for the treatment of KRAS-mutated, recurrent low-grade serous ovarian cancer.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

MTC has, however, already been studied as an Alzheimer's therapy, so TauRx selected ... TauRx says it will file for approval of HMTM in the US and Canada next year, and before that it plans ...

With so many recent instances of pharmaceutical supply chains slowing or breaking down, there have been calls to reshore production, by governments and companies alike, in both the US and Europe.